Search results
Atosiban, sold under the brand name Tractocile among others, is an inhibitor of the hormones oxytocin and vasopressin. It is used as an intravenous medication as a labour repressant (tocolytic) to halt premature labor. It was developed by Ferring Pharmaceuticals in Sweden and first reported in the literature in 1985.
Atosiban reduces the frequency of uterine contractions to delay pre-term birth in adult females and induces uterine quiescence 5, 1. Mechanism of action. Atosiban is a synthetic peptide oxytocin antagonist 5, 1. It resembles oxytocin with has modifications at the 1, 2, 4, and 8 positions.
Description: Mechanism of Action: Atosiban is an oxytocin peptide analogue.It competitively inhibits oxytocin receptors thereby causing a reduction in oxytocin-mediated release of inositol triphosphate (IP3) from myometrial cell membranes, which consequently causes decreased Ca release and extracellular Ca influx, ultimately causing a reduced frequency of uterine contractions.
The active substance in Tractocile, atosiban, is an antagonist of the natural hormone oxytocin. This means that atosiban blocks the action of oxytocin. Oxytocin is the hormone involved in starting contractions of the womb. By blocking the action of oxytocin, Tractocile prevents contractions and causes the womb to relax, helping to delay birth.
The active substance in Atosiban SUN, atosiban, is an antagonist of the natural hormone oxytocin. This means that atosiban blocks the action of oxytocin. Oxytocin is the hormone involved in starting contractions of the womb. By blocking the action of oxytocin, Atosiban SUN prevents contractions and causes the womb to relax, helping to delay birth.
Atosiban is a synthetic peptide oxytocin antagonist. It resembles oxytocin with has modifications at the 1, 2, 4, and 8 positions. The N-terminus of the cysteine residue is deaminated to form 3-mercaptopropanic acid at position 1, at position 2 L-tyrosine is modified to D-tyrosine with an ethoxy group replacing the phenol, threonine replaces glutamine at postion 4, and ornithine replaces ...
Atosiban Mechanism of action. Atosiban is a peptide analogue of oxytocin that is an antagonist at oxytocin receptors in the decidua and myometrium, reducing the release of intracellular Ca 2+. Pharmacokinetics. Atosiban is given initially by intravenous bolus injection followed by an infusion; it has a short half-life (0.2–1.7 h). Unwanted ...
Oct 2, 2019 · Atosiban was administered to inhibit uterine contractions (He et al., 2016a; Hebisha et al., 2016). Atosiban is a uterine-specific, mixed vasopressin V1-a and oxytocin-receptor antagonist, that is registered for tocolysis in imminent premature birth. It also inhibits uterine contractility in nonpregnant women.
Jun 21, 2021 · Atosiban is a synthesised cyclic nonapeptide that behaves as a competitive oxytocin receptor antagonist to inhibit the oxytocin-mediated increase of intracellular calcium concentration that induces uterine muscle contractions.9,10 In the late 1980s, the first pilot study of atosiban analysed its effect on 13 patients and demonstrated its dose ...
For atosiban. For intravenous infusion ( Tractocile ® concentrate for intravenous infusion), manufacturer advises give continuously in Glucose 5% or Sodium chloride 0.9%. Withdraw 10 mL infusion fluid from 100-mL bag and replace with 10 mL atosiban concentrate (7.5 mg/mL) to produce a final concentration of 750 micrograms/mL.
